Drug intelligence / Profile preview

convalescent anti-SARS-CoV-2 MBT plasma

Development stage: Phase 2
Lead developer: Instituto Grifols
Modality: Albumin → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Convalescent anti-SARS-CoV-2 MBT plasma is a biological product derived from the plasma of individuals who have recovered from Coronavirus Disease 2019 (COVID-19). The plasma undergoes Methylene Blue Treated (MBT) pathogen reduction. It is administered via intravenous infusion and is being investigated for its potential to reduce all-cause mortality in hospitalized COVID-19 patients requiring intensive care unit (ICU) admission. Instituto Grifols, S.A. is the lead sponsor for its development.

Beyond the preview

Go deeper on convalescent anti-SARS-CoV-2 MBT plasma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on convalescent anti-SARS-CoV-2 MBT plasma.

Explore the full profile